



ASX ANNOUNCEMENT

FebriDx® U.S. Commercial Update Webinar Invitation

Follow our progress:

Did you know that alongside ASX updates, Lumos provides updates across a range of channels?

- To subscribe for all our news delivered to your inbox, please visit <https://lumosdiagnostics.com/invest>.
- Find / follow us on LinkedIn here: www.linkedin.com/company/lumos-diagnostics

MELBOURNE, Australia (4 June 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite investors to attend a virtual briefing on Thursday, 11 June at 10:30am (AEST).

During the briefing, Tommy Hall, Lumos Diagnostics’ Director of U.S. Sales, together with PHASE Scientific’s VP of Commercial Operations, Bob Gergen, will provide an update on the commercialisation of FebriDx® in the U.S., following the achievement of FDA CLIA waiver clearance (ASX: 27 March 2026).

Since receiving CLIA waiver status, Lumos and PHASE Scientific have accelerated the rollout of commercial operations across the U.S., with FebriDx® now deployed across more than 100 healthcare locations spanning 18 states. Collectively, these sites performed approximately 195,000 influenza tests over the past year.

This marks a meaningful milestone in the product’s adoption for respiratory infection management and reflects growing demand for rapid diagnostic tools capable of delivering actionable insights at the point of care. The expanding commercial footprint now includes urgent care, primary care, concierge medicine and collegiate health settings, highlighting the broad applicability of FebriDx® across multiple healthcare channels.

The discussion will also cover the strong foundations being established to support FebriDx® from a reimbursement perspective, including ongoing progress with Medicare, Medicaid and private payor engagement.

Managing Director and CEO, Doug Ward, will also join the briefing, with the presentation to be followed by a Q+A session.

For personal use only

Registration information:

Date: Thursday, 11 June, 2026 from 10:30am AEST (Sydney, Canberra, Melbourne)

Registration: Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_3vSVG5koRLOJaizY8p8gJg

Once the registration form is completed, participants will receive a confirmation email with details on how to access the briefing.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About FebriDx®

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections after 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

Recent CLIA waiver clearance expands the applicability of FebriDx® to over 300,000 locations across the US¹, covering a broad range of healthcare settings, spanning primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres that hold a Certificate of Waiver. This milestone marks a significant commercial achievement for Lumos, positioning FebriDx® to reach tens of millions more patients without the need for complex laboratory infrastructure or specialised training.

With the CLIA waiver now granted, FebriDx® can be deployed more broadly, potentially reaching 80 million patients² per annum in the US who present with acute respiratory infections at primary care and urgent care centres. This unlocks a US\$1.0+ billion market opportunity, approximately 15 times larger than the market opportunity available to the Company under the previous moderate-complexity classification.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

¹Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database). ²Precision Business Insights, US Acute Respiratory Infections, 2024.

For personal use only

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres - Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598

For personal use only